STOCK TITAN

Context Therapeutics Inc - CNTX STOCK NEWS

Welcome to our dedicated news page for Context Therapeutics (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Context Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Context Therapeutics's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Context Therapeutics Inc

Nasdaq:CNTX

CNTX Rankings

CNTX Stock Data

23.79M
13.89M
6.86%
30.06%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Philadelphia

About CNTX

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.